An optimal antitumor response by a novel CEA/CD3 bispecific antibody for colorectal cancers.

ABSTRACT:

Background

CD3-based bispecific T cell engagers (bsTCEs) are one of the most promising bispecific antibodies for effective cancer treatments. To elicit target-specific T cell-mediated cytotoxicity, these bsTCEs contain at least one binding unit directed against a tumor antigen and another binding unit targeting CD3 in T cell receptor complex. Development of CD3-based bsTCEs, however, has been severely hampered by dose-limiting toxicities due to cytokine release syndrome. To address this limitation, we developed a novel functionally trivalent T cell engager (t-TCE) antibody containing affinity-reduced CD3 binding unit positioned to ensure monovalent CD3 engagement, in combination with bivalent tumor antigen binding of carcinoembryonic antigen (CEA).

Methods

We modeled the var

SUBMITTER: Wang N 

PROVIDER: S-EPMC8220303 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature